In Vivo SELEX: A Strategy for Identifying Ovarian Cancer-Specific Aptamers

Ovarian cancer is a significant and life-threatening malignancy among women worldwide. Selective tumor targeting by molecular agents is essential for the development of effective therapeutics and diagnostics. Recognizing the disparities between in vivo and in vitro environments, we have implemented an in vivo SELEX strategy to identify DNA aptamers capable of specifically localizing to ovarian tumors in situ. Aptamer L1 has emerged as a promising candidate with a high binding affinity to Insulin-like Growth Factor Binding Protein 3 (IGFBP3), a tumor-promoting protein overexpressed in ovarian cancer. Notably, aptamer L1 effectively downregulates IGFBP3 expression and suppresses ovarian cancer cell proliferation. The unique molecular characteristics of aptamer L1 underscore its potential as a theranostic agent for ovarian cancer.

Authors

Institutions

Publication Details

Journal
ACS Applied Materials & Interfaces
Published
2025-11-11
DOI
https://doi.org/10.1021/acsami.5c17714
Primary Topic
Advanced biosensing and bioanalysis techniques
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Vivo SELEX: A Strategy for Identifying Ovarian Cancer-Specific Aptamers

Fen-Sheng Qiu, Weihong Tan, Yuanming Shen, Tao Zhu et al.
ACS Applied Materials & Interfaces
Advanced biosensing and bioanalysis techniques
article

In Vivo SELEX: A Strategy for Identifying Ovarian Cancer-Specific Aptamers

Fen-Sheng Qiu, Weihong Tan, Yuanming Shen, Tao Zhu, Xiaona Fang, Hui Meng, Zhaofeng Luo, Guomiao Liao, Ruibin Jiang, Siru Zhang, chanyuan li, Zheng Zhang, Longjie Li, Weichang Chen, Huarong Tang
article en

Abstract

Ovarian cancer is a significant and life-threatening malignancy among women worldwide. Selective tumor targeting by molecular agents is essential for the development of effective therapeutics and diagnostics. Recognizing the disparities between in vivo and in vitro environments, we have implemented an in vivo SELEX strategy to identify DNA aptamers capable of specifically localizing to ovarian tumors in situ. Aptamer L1 has emerged as a promising candidate with a high binding affinity to Insulin-like Growth Factor Binding Protein 3 (IGFBP3), a tumor-promoting protein overexpressed in ovarian cancer. Notably, aptamer L1 effectively downregulates IGFBP3 expression and suppresses ovarian cancer cell proliferation. The unique molecular characteristics of aptamer L1 underscore its potential as a theranostic agent for ovarian cancer.

ACS Applied Materials & InterfacesVol. 17(46)
Gynecologic Oncology Group (US), Sun Yat-sen University (CN), Hunan University (CN), Anhui Medical University (CN), Chinese Academy of Sciences (CN), Harbin Institute of Technology (CN), Wenzhou Medical University (CN), Zhejiang Cancer Hospital (CN), Theranostics (New Zealand) (NZ), Women's Hospital, School of Medicine, Zhejiang University (CN), Sun Yat-sen University Cancer Center (CN), Lifan (China) (CN), State Key Laboratory of Chemobiosensing and Chemometrics (CN), State Key Laboratory of Oncology in South China, Zhejiang University (CN)
Openalex Percentile: Top 69%
Advanced biosensing and bioanalysis techniques
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.